Trial in Progress: Asciminib in Monotherapy 4 CML (AIM4CML), a Phase IIIb Study of Asciminib Monotherapy in Patients with Chronic Myeloid Leukemia in Chronic Phase without or with T315I Mutations

被引：1

作者：

Andorsky, David ^{[1
,10
]}

Tomassetti, Sarah ^{[2
,3
]}

Deutsch, Yehuda E. ^{[4
]}

Broun, E. Randolph ^{[5
]}

Issa, Ghayas C. ^{[6
]}

Levy, Moshe Y. ^{[7
]}

Deininger, Michael W. ^{[8
]}

Maegawa, Rodrigo ^{[9
]}

Shrestha, Alok ^{[9
]}

Mauro, Michael J. ^{[10
]}

机构：

[1] Rocky Mt Canc Ctr, Boulder, CO USA

[2] Harbor UCLA Med Ctr, Redondo Beach, CA USA

[3] Univ Calif Los Angeles, David Geffen Sch Med, Redondo Beach, CA USA

[4] H Lee Moffitt Canc Ctr & Res Inst, Mem Hlth Syst, Dept Malignant Hematol & Cellular Therapy, Pembroke Pines, FL USA

[5] Oncol Hematol Care Inc, Cincinnati, OH USA

[6] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[7] Baylor Scott & White Res Inst, Dallas, TX USA

[8] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT USA

[9] Novartis Pharmaceut, E Hanover, NJ USA

[10] Mem Sloan Kettering Canc Ctr, Leukemia Serv, Myeloproliferat Neoplasms Program, 1275 York Ave, New York, NY 10021 USA

来源：

关键词：

D O I：

10.1182/blood-2021-147337

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3599

引用

页数：6